TY - JOUR
T1 - Potentiation by a sodium channel activator of effects of lithium ion on cyclic AMP, cyclic GMP and inositol phosphates
AU - Kanba, S.
AU - Yagi, G.
AU - Nakaki, T.
AU - Kato, R.
AU - Richelson, E.
PY - 1991/5
Y1 - 1991/5
N2 - The effects of the lithium ion (Li+ ) on receptor-mediated synthesis of second messengers were determined, when cellular sodium channels were quiescent or excited, using the murine neuroblastoma clone (N1E-115). In this clone, lithium inhibited the receptor-mediated synthesis of cyclic AMP and cyclic GMP and it also increased the accumulation of inositol phosphates by a receptor-mediated process. When veratridine (20 μM) excited the sodium channel, the effects of lithium were potentiated. However, tetrodotoxin, a sodium channel blocker, completely prevented this potentiation. These results suggest that when neurons are depolarizing actively and intraneuronal levels of lithium increase by entry through the sodium channel, lithium has a more potent intracellular effect. As a result, lithium would have more potent and selective effects in those pathologically-active neurons underlying manic-depressive disorder.
AB - The effects of the lithium ion (Li+ ) on receptor-mediated synthesis of second messengers were determined, when cellular sodium channels were quiescent or excited, using the murine neuroblastoma clone (N1E-115). In this clone, lithium inhibited the receptor-mediated synthesis of cyclic AMP and cyclic GMP and it also increased the accumulation of inositol phosphates by a receptor-mediated process. When veratridine (20 μM) excited the sodium channel, the effects of lithium were potentiated. However, tetrodotoxin, a sodium channel blocker, completely prevented this potentiation. These results suggest that when neurons are depolarizing actively and intraneuronal levels of lithium increase by entry through the sodium channel, lithium has a more potent intracellular effect. As a result, lithium would have more potent and selective effects in those pathologically-active neurons underlying manic-depressive disorder.
UR - http://www.scopus.com/inward/record.url?scp=0025905518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025905518&partnerID=8YFLogxK
U2 - 10.1016/0028-3908(91)90012-Z
DO - 10.1016/0028-3908(91)90012-Z
M3 - Article
C2 - 1650929
AN - SCOPUS:0025905518
SN - 0028-3908
VL - 30
SP - 497
EP - 500
JO - Neuropharmacology
JF - Neuropharmacology
IS - 5
ER -